Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
Overview
The past few years have been challenging for Moderna (NASDAQ:MRNA) whose results haven't been as strong as demand for its COVID vaccine has diminished drastically. Lately, however, there's been a sharp and sudden surge in its share price. The stock has been acting like a volatile biotech stock that just obtained approval for a new drug.
While that isn't the case, there's been a flurry of hype and excitement around a personalized cancer vaccine that it's been working on with Merck. It's a promising growth opportunity for both companies. But with Moderna already soaring more than 550% this year, has it gotten too expensive to buy right now?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.